| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 4000610 | Urologic Oncology: Seminars and Original Investigations | 2011 | 7 Pages | 
Abstract
												Long-term results with a single HDCT cycle or a low dose-intensity multicycle HDCT regimen remained poor in patients with adverse prognostic features. The tandem HDCT regimen represents a major option for refractory GCTs and relapsed tumors in third-line or later therapy, while a single course of HDCT should be abandoned for these patients.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Oncology
												
											Authors
												Ugo M.D., Giovanni M.D., Roberto M.D., Giorgio M.D., Michela Ph.D., Giorgio M.D., Maurizio M.D., 
											